SynAct Pharma AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Net Income	-110.83	-82.4	-215.81	-99.21	-69.3	Upgrade
Depreciation & Amortization	-	0.62	75.34	1.02	0.09	Upgrade
Loss (Gain) From Sale of Assets	-	-0.05	-0.04	-0.01	-	Upgrade
Stock-Based Compensation	-	10.07	7.88	-	-	Upgrade
Other Operating Activities	6.01	0.85	2.09	1	-2.88	Upgrade
Change in Accounts Receivable	-	-19.63	19.87	-19.31	-1.21	Upgrade
Change in Accounts Payable	-	7.33	5.11	0.18	1.44	Upgrade
Change in Other Net Operating Assets	7.49	-5.97	5.39	-1.22	6.87	Upgrade
Operating Cash Flow	-97.33	-89.2	-100.18	-117.56	-65	Upgrade
Investment in Securities	-	-	0.37	0.03	-0.01	Upgrade
Investing Cash Flow	-	-	0.37	0.03	-0.01	Upgrade
Long-Term Debt Repaid	-	-0.6	-0.73	-0.98	-0.08	Upgrade
Net Debt Issued (Repaid)	-	-0.6	-0.73	-0.98	-0.08	Upgrade
Issuance of Common Stock	-	94.14	59.46	228.95	80	Upgrade
Other Financing Activities	90.46	-6.14	-4.75	-27.25	-5.6	Upgrade
Financing Cash Flow	90.46	87.41	53.98	200.71	74.32	Upgrade
Foreign Exchange Rate Adjustments	-0.93	0.61	-0.03	1.06	0.13	Upgrade
Miscellaneous Cash Flow Adjustments	-	-0	-	0	-0	Upgrade
Net Cash Flow	-7.8	-1.19	-45.85	84.25	9.45	Upgrade
Cash Interest Paid	2.38	0.98	0.12	0.12	0.11	Upgrade
Cash Income Tax Paid	-8.16	-8.43	-8.47	-7.86	-4.63	Upgrade
Levered Free Cash Flow	-62.35	-62.5	18.74	-86.61	-43.28	Upgrade
Unlevered Free Cash Flow	-60.82	-61.99	19.24	-86.43	-43.21	Upgrade
Change in Working Capital	7.49	-18.28	30.37	-20.35	7.1	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.